标题
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 29, Issue suppl_1, Pages i20-i27
出版商
Oxford University Press (OUP)
发表日期
2018-01-20
DOI
10.1093/annonc/mdx704
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer
- (2018) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component
- (2017) James Chih-Hsin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
- (2017) June-Koo Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
- (2017) Chee Khoon Lee et al. Journal of Thoracic Oncology
- Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer
- (2017) Suzanne Jenkins et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Programmed death-ligand 1 expression and T790M status in EGFR -mutant non-small cell lung cancer
- (2017) Akito Hata et al. LUNG CANCER
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- (2017) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
- (2017) Rafael Rosell et al. Lancet Respiratory Medicine
- Crystal digital droplet PCR for detection and quantification of circulating EGFR sensitizing and resistance mutations in advanced non-small cell lung cancer
- (2017) Cécile Jovelet et al. PLoS One
- Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies
- (2016) David Planchard et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
- (2016) P. Ballard et al. CLINICAL CANCER RESEARCH
- Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial
- (2016) C. Jovelet et al. CLINICAL CANCER RESEARCH
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer
- (2016) Geoffrey R. Oxnard et al. JOURNAL OF CLINICAL ONCOLOGY
- Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations
- (2016) Yang-Si Li et al. Journal of Thoracic Oncology
- LBA2_PR: Osimertinib (AZD9291) in pre-treated pts with T790M-positive advanced NSCLC: updated Phase 1 (P1) and pooled Phase 2 (P2) results
- (2016) J. Yang et al. Journal of Thoracic Oncology
- First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases
- (2016) Martin Schuler et al. Journal of Thoracic Oncology
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
- (2016) Glenwood Goss et al. LANCET ONCOLOGY
- Update to Rociletinib Data with the RECIST Confirmed Response Rate
- (2016) Lecia V. Sequist et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB
- (2015) Kailong Lin et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
- (2015) C. A. Eberlein et al. CANCER RESEARCH
- The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies
- (2015) M. J. Niederst et al. CLINICAL CANCER RESEARCH
- Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses
- (2015) T. K. Sundaresan et al. CLINICAL CANCER RESEARCH
- Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR
- (2015) M. Watanabe et al. CLINICAL CANCER RESEARCH
- Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
- (2015) Karen Kelly et al. JOURNAL OF CLINICAL ONCOLOGY
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
- (2015) Bin-Chi Liao et al. Journal of Thoracic Oncology
- Treatment and survival of patients with EGFR -mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis
- (2015) Justine L. Kuiper et al. LUNG CANCER
- Abstract B153: Effect of food and gastric pH modifiers on the pharmacokinetics of AZD9291
- (2015) Karthick Vishwanathan et al. MOLECULAR CANCER THERAPEUTICS
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer
- (2015) Muhammed Murtaza et al. Nature Communications
- Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing
- (2014) H. A. Yu et al. ANNALS OF ONCOLOGY
- The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
- (2014) C. Costa et al. CLINICAL CANCER RESEARCH
- Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations
- (2014) Toshihiko Iuchi et al. International Journal of Clinical Oncology
- A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer
- (2014) KAZUYA OFUJI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor
- (2014) M. Raymond V. Finlay et al. JOURNAL OF MEDICINAL CHEMISTRY
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
- (2014) Takashi Seto et al. LANCET ONCOLOGY
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
- (2014) D. A. E. Cross et al. Cancer Discovery
- Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers
- (2013) H. A. Yu et al. CLINICAL CANCER RESEARCH
- Gefitinib Versus Placebo in Completely Resected Non–Small-Cell Lung Cancer: Results of the NCIC CTG BR19 Study
- (2013) Glenwood D. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations
- (2011) R. Rosell et al. CLINICAL CANCER RESEARCH
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation
- (2010) R. Porta et al. EUROPEAN RESPIRATORY JOURNAL
- Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance
- (2009) G. N. Naumov et al. CLINICAL CANCER RESEARCH
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP
- (2008) C.-H. Yun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More